Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Current Assets (2021 - 2025)

Valion Bio has reported Current Assets over the past 5 years, most recently at $13.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 392.84% year-over-year to $13.0 million; the TTM value through Dec 2025 reached $13.0 million, up 392.84%, while the annual FY2025 figure was $13.0 million, 392.84% up from the prior year.
  • Current Assets for Q4 2025 was $13.0 million at Valion Bio, up from $3.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $14.3 million in Q4 2021 and troughed at $1.3 million in Q1 2025.
  • A 5-year average of $6.1 million and a median of $4.7 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 62.87% in 2022 and later surged 392.84% in 2025.
  • Year by year, Current Assets stood at $14.3 million in 2021, then plummeted by 62.87% to $5.3 million in 2022, then dropped by 12.33% to $4.7 million in 2023, then plummeted by 43.27% to $2.6 million in 2024, then skyrocketed by 392.84% to $13.0 million in 2025.
  • Business Quant data shows Current Assets for TIVC at $13.0 million in Q4 2025, $3.7 million in Q3 2025, and $1.8 million in Q2 2025.